Long-acting preparations of exenatide
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide products on the market, twice-daily Byetta™ and once-weekly Bydureon™ (both Amylin Pharmaceuticals, San Diego, CA, USA), are still not perfect. Many researchers have attempted to prolong the acting time of exenatide by preparing sustained-release dosage forms, modifying its structure, gene therapies, and other means. This review summarizes recent advances in long-acting exenatide preparations. Keywords: exendin-4, diabetes mellitus type 2, sustained release, long acting, extended release, microsphere
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Foreign body reaction to biomaterials
Anderson, J. M., Rodriguez, A., & Chang, D. T. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2007.11.004 · Cited by 5,138
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“Liraglutide has been developed as a once-daily treatment for type 2 diabetes (marketed as Victoza [Novo Nordisk, Bagsværd, Denmark]) as an adjunctive therapy.(64) Agersø et al investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy male subjects following 7 days’ treatment with NN2211…”
McGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 1×
“In comparative trials, compared with twice-daily exenatide, Bydureon microspheres improved hemoglobin A1c (HbA 1c ) and reduced fasting plasma glucose, with fewer gastrointestinal side effects, no increased risk of hypoglycemia and with similar reductions in bodyweight.(8,20,21) Norwood et al carried out a 2-year tria…”
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“Agersø et al investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy male subjects following 7 days’ treatment with NN2211 (liraglutide).(65) Results showed that liraglutide had a half-life of 12.”
Exenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55
Norwood, P., Liutkus, J. F., Haber, H., Pintilei, E., Boardman, M. K., & Trautmann, M. E. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.007 · Cited by 24 · cited 2×
“In comparative trials, compared with twice-daily exenatide, Bydureon microspheres improved hemoglobin A1c (HbA 1c ) and reduced fasting plasma glucose, with fewer gastrointestinal side effects, no increased risk of hypoglycemia and with similar reductions in bodyweight.(8,20,21) Norwood et al carried out a 2-year tria…”
Cited by
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Development of Cagrilintide, a Long-Acting Amylin Analogue
Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00565 · Cited by 129
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences
Forouzanmehr, B., Hemmati, M. A., Atkin, S. L., Jamialahmadi, T., Yaribeygi, H., & Sahebkar, A. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-024-03384-1 · Cited by 3
Metadata
- Authors
- Yuan, W., Cai, Y., Liangming Wei, L., Ma, L., Huang, X., Tao, A., & Liu, Z.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2013-09
- Volume
- 7
- Pages
- 963
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2157365347
- Cited by
- 57
- References
- 9
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-acting preparations of exenatide. https://app.cochat.ai/papers/10.2147/dddt.s46970
- The paper
- Yuan, W., Cai, Y., Liangming Wei, L., Ma, L., Huang, X., Tao, A., & Liu, Z. (2013). Long-acting preparations of exenatide. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s46970
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.